Smarter cancer care
Exact Sciences brings the promise of precision medicine to life with Oncotype IQ, a full suite of genomic tests.
LEARN MORE

Visit us at the St. Gallen Congress 2021

Virtual exhibition on 17-21 March

Join our virtual satellite symposium on Friday, 19 March at 12:45–13:45 CET: "Confidence in treatment decisions for HR+, HER2- early-stage breast cancer patients"

Landmark RxPONDER Trial Results

Presented at the 2020 SABCS

New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25

Exact Sciences' Response to COVID-19

A Letter from our CEO, Kevin Conroy

"Cancer doesn’t stop and neither will we. Our team’s commitment to serving patients is unwavering, and we’ll continue working hard to do just that."
Improving Patient Outcomes

Contact Us

 Get in Touch
Copyright © 2004- Genomic Health, Inc., an Exact Sciences corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc., an Exact Sciences corporation.
Making cancer care smarter.®
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.